Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer

ConferenceATNM-400Positive

AI Analysis

Summary

Actinium presented new preclinical data for ATNM-400 in KRAS and EGFR mutant models at SNMMI 2026, suggesting a potential mutation-agnostic approach for treating non-small cell lung cancer.

Importance:5/10

Sentiment:

0.50

ATNM-400NSCLCKRAS mutantEGFR mutantSNMMI 2026preclinical datamutation-agnostic

Related Companies

$ATNM

Read the original article

Published by yahoo_finance on June 3, 2026 12:00 PM

Read Original